Clinical trial
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria…
NCT04152200 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT04152200 |
|---|---|
| Title | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 |
| Official title | ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) |
| Acronym | ILLUMINATE-C |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hyperoxaluria Type 1, Primary Hyperoxaluria |
| Intervention type | Drug |
| Interventions | Lumasiran |
| Enrollment | 21 |
| Start date | Jan 21, 2020 |
| Primary completion | May 18, 2021 |
| Completion | Jun 23, 2025 |
| First posted | Nov 5, 2019 |
| Last update posted | Jul 18, 2025 |
| Countries | Australia, Belgium, France, Israel, Italy, Jordan, Lebanon, Netherlands, Turkey (Türkiye), United Arab Emirates, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: